Chai Discovery, a San Francisco startup that builds artificial intelligence models to design new drug molecules from scratch, has raised $400 million in a Series C round that pushes its valuation to $3.8 billion — nearly triple the $1.3 billion mark it hit just seven months earlier.
The round, announced July 14, 2026, was led by Index Ventures, with participation from Kleiner Perkins, Sequoia Capital and Dimension. New backers including Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures and Avra Capital joined the raise, alongside existing investors Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom and Yosemite. The financing brings Chai's total capital raised to roughly $630 million since it was founded in 2024, a trajectory that began with a $30 million seed round, continued with a $70 million Series A in August 2025, and a $130 million Series B that December.
Founded by Joshua Meier, Jack Dent, Matthew McPartlon and Jacques Boitreaud — a team with backgrounds spanning OpenAI, Meta FAIR and Stripe — Chai builds generative AI models that predict and "reprogram" the interactions between molecules, aiming to replace much of the trial-and-error at the front end of pharmaceutical R&D with computational design. The company's platform is already deployed inside Eli Lilly and Pfizer, and, as of this month, Novartis, which signed on for a wide-ranging project to develop antibodies against multiple therapeutic targets.
"Tomorrow's medicines should be designed with the precision, speed and scale of modern engineering, and this support helps us move faster towards that future," said Joshua Meier, co-founder and CEO of Chai Discovery. "AI drug discovery has moved from promise to deployment, and Chai's models are already unlocking progress for our partners — enabling them to design better molecules, move faster against difficult targets, and take on challenges that traditional discovery methods have struggled to solve."
The technical case for that claim rests on Chai's antibody-design models. Chai-2, released in 2025, became the first zero-shot generative platform for fully de novo antibody design to post double-digit experimental hit rates — roughly 16% to 20%, according to the company, compared with success rates below 1% for prior computational approaches. Its successor, Chai-3, further improves target success rates and binding affinity, producing antibodies that Chai says bind substantially more tightly to intended targets and can unlock targets that have "long resisted traditional computational and laboratory methods."
Investors framed the round as a bet on commercial traction rather than research promise alone. "It's rare to find founders who have the technical brilliance to push the frontier and the clarity to turn that into real commercial traction," said Nina Achadjian, partner at Index Ventures. "Josh, Jack, Matt, Jacques and the team aren't building toward real-world deployment — they're already there, with deployments already at the world's largest pharma companies." Sequoia Capital partner Pat Grady struck a similar note: "For a long time, there's been a dream that AI will solve [drug discovery]. Chai's product velocity and real-world partnerships with Eli Lilly, Pfizer, and more of the biggest names in pharma are starting to turn this dream into a reality." Dimension founder Zavain Dar called the check "the largest check we've ever written," while Kleiner Perkins partner Ilya Fushman said Chai's models are "already being used by some of the world's largest pharma companies" at a pace of advancement he called "remarkable."
Why It Matters
Chai's raise is fresh evidence that the AI-biotech convergence has moved from speculative research bets to production infrastructure with paying enterprise customers — pharma companies licensing frontier models and, in Lilly's case, commissioning bespoke versions trained on proprietary data. That shifts the economics behind AI funding rounds: investors are no longer pricing model capability alone, they are pricing compute-to-outcome efficiency, or how many de novo molecular designs a given training and inference budget can turn into validated, developable leads. A jump from sub-1% to 16%-20% experimental hit rates is exactly the kind of compounding return that justifies a mega-round at a moment when capital for pure model-scaling plays is getting harder to raise. It also signals that big pharma is willing to outsource discovery infrastructure to external AI labs rather than build everything in-house, echoing the compute-provider dynamic playing out between hyperscalers and enterprise AI customers elsewhere in the industry.
What to Watch
The next test for Chai is whether Chai-3's improved hit rates and binding affinity translate into actual clinical candidates advancing through Lilly, Pfizer and Novartis pipelines — the metric that will separate a $3.8 billion valuation grounded in real revenue from one built on model benchmarks alone. Watch for disclosure of specific programs or milestone payments tied to the pharma partnerships, additional big-pharma logos following Novartis's July signing, and whether rival AI-driven molecular design startups respond with financings or partnerships of their own as mega-rounds continue to sweep the sector through the rest of 2026.
"AI drug discovery has moved from promise to deployment, and Chai's models are already unlocking progress for our partners, enabling them to design better molecules, move faster against difficult targets, and take on challenges that traditional discovery methods have struggled to solve."- Joshua Meier, Co-founder and CEO, Chai Discovery